Effect of controlled-release levodopa on the microstructure of sleep in Parkinson’s disease

Wailke, S.; Herzog, Jan; Witt, Karsten; Deuschl, Günther; Volkmann, Jens

doi:10.1111/j.1468-1331.2010.03213.x

Cited by 59 publications

(53 citation statements)

References 31 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These symptoms are similar to those observed in people with PD, especially in the advanced form of the disease [1,2]. It also confirmed that L-dopa tends to improve sleep parameters such as the relative time awake, sleep efficiency, and REM sleep time.…”

Section: Discussionsupporting

confidence: 79%

“…Moreover, 15-60% of people with PD have rapid eye movement (REM) sleep behavior disorder, which consists of excessive motor activity during dreaming in association with loss of skeletal muscle atonia of REM sleep [1,2]. The effects of dopaminergic drugs on sleep and alertness in people with PD are difficult to analyze because they may improve sleep quality, partly through reducing motor symptoms, but also increase daytime sleepiness and cause insomnia.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of melatonin on sleep disorders in a monkey model of Parkinson's disease

et al. 2015

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 79%

Section: Introductionmentioning

confidence: 99%

Effect of melatonin on sleep disorders in a monkey model of Parkinson's disease

et al. 2015

View full text Add to dashboard Cite

“…Specifically, the data suggests that low doses of pharmacological agents that increase dopamine can improve sleep while higher doses delay the onset of sleep and decrease total sleep time (Diederich and McIntyre, 2012; Schafer and Greulich, 2000; Yong et al, 2011). Further work will be required to see if controlling the timing of the dosing of the L-DOPA and related compounds can minimize the undesirable sleep disruptions caused by dopaminergic medications (Wailke et al, 2011). For example, one simple prediction is that using pharmacological tools to reinforce the normal daily rhythm of DA with higher levels of DA activity during the day with lower levels at night may improve motor function without disrupting sleep and circadian function.…”

Section: Dopaminergic Treatments For the Core Motor Symptoms Of Pd Mamentioning

confidence: 99%

Circadian dysfunction may be a key component of the non-motor symptoms of Parkinson's disease: Insights from a transgenic mouse model

Willison

Kudo

Loh

et al. 2013

Experimental Neurology

View full text Add to dashboard Cite

Sleep disorders are nearly ubiquitous among patients with Parkinson’s disease (PD), and they manifest early in the disease process. While there are a number of possible mechanisms underlying these sleep disturbances, a primary dysfunction of the circadian system should be considered as a contributing factor. Our laboratory’s behavioral phenotyping of a well-validated transgenic mouse model of PD reveals that the electrical activity of neurons within the master pacemaker of the circadian system, the suprachiasmatic nuclei (SCN), is already disrupted at the onset of motor symptoms, although the core features of the intrinsic molecular oscillations in the SCN remain functional. Our observations suggest that the fundamental circadian deficit in these mice lies in the signaling output from the SCN, which may be caused by known mechanisms in PD etiology: oxidative stress and mitochondrial disruption. Disruption of the circadian system is expected to have pervasive effects throughout the body and may itself lead to neurological and cardiovascular disorders. In fact, there is much overlap in the non-motor symptoms experienced by PD patients and in the consequences of circadian disruption. This raises the possibility that the sleep and circadian dysfunction experienced by PD patients may not merely be a subsidiary of the motor symptoms, but an integral part of the disease. Furthermore, we speculate that circadian dysfunction can even accelerate the pathology underlying PD. If these hypotheses are correct, more aggressive treatment of the circadian misalignment and sleep disruptions in PD patients early in the pathogenesis of the disease may be powerful positive modulators of disease progression and patient quality of life.

show abstract

“…Dopaminergic medications may have a role in improving sleep quality. In the context of nighttime motor dysfunction, controlled release formulation of levodopa/carbidopa may be considered, although its chronic effects on sleep architecture require further study (23, 30). Dopamine agonists have garnered recent interest in treating sleep disorders in PD.…”

Section: Introductionmentioning

confidence: 99%

Sleep and Circadian Rhythm Disorders in Parkinson’s Disease

Gros

Videnović

2017

Curr Sleep Medicine Rep

View full text Add to dashboard Cite

Purpose of review Sleep disorders are among the most challenging non-motor features of Parkinson’s disease (PD) and significantly affect quality of life. Research in this field has gained recent interest among clinicians and scientists and is rapidly evolving. This review is dedicated to sleep and circadian dysfunction associated with PD. Recent findings Most primary sleep disorders may co-exist with PD; majority of these disorders have unique features when expressed in the PD population. Summary We discuss the specific considerations related to the common sleep problems in Parkinson’s disease including insomnia, rapid eye movement sleep behavior disorder, restless legs syndrome, sleep disordered breathing, excessive daytime sleepiness and circadian rhythm disorders. Within each of these sleep disorders, we present updated definitions, epidemiology, etiology, diagnosis, clinical implications and management. Furthermore, areas of potential interest for further research are outlined.

show abstract

Effect of controlled-release levodopa on the microstructure of sleep in Parkinson’s disease

Abstract: Levodopa/carbidopa CR has previously been found effective for treating night-time akinesia, but according to this study, it has no impact on the altered sleep structure in PD.

Cited by 59 publications

References 31 publications

Effect of melatonin on sleep disorders in a monkey model of Parkinson's disease

Effect of melatonin on sleep disorders in a monkey model of Parkinson's disease

Circadian dysfunction may be a key component of the non-motor symptoms of Parkinson's disease: Insights from a transgenic mouse model

Sleep and Circadian Rhythm Disorders in Parkinson’s Disease

Contact Info

Product

Resources

About